Literature DB >> 1727099

Evidence for sexual transmission of human T lymphotropic virus type II.

B Hjelle, S Cyrus, S G Swenson.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1727099     DOI： 10.7326/0003-4819-116-1-90

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  6 in total

1.  Molecular evidence for infection by HTLV-2 among individuals with negative serological screening tests for HTLV antibodies.

Authors:  R Ishak; A C R Vallinoto; V N Azevedo; A C P Vicente; W W Hall; M O G Ishak
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

2.  Different population dynamics of human T cell lymphotropic virus type II in intravenous drug users compared with endemically infected tribes.

Authors:  M Salemi; M Lewis; J F Egan; W W Hall; J Desmyter; A M Vandamme
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

3.  HTLV-2 infection in injection drug users in King County, Washington.

Authors:  Joseph R Zunt; Ken Tapia; Hanne Thiede; Rong Lee; Holly Hagan
Journal:  Scand J Infect Dis       Date:  2006

4.  HTLV-I and HTLV-II infections among HIV-1 seropositive patients in Sao Paulo, Brazil.

Authors:  A C de Araujo; J S Casseb; E Neitzert; M L de Souza; F Mammano; A Del Mistro; A De Rossi; L Chieco-Bianchi
Journal:  Eur J Epidemiol       Date:  1994-04       Impact factor: 8.082

5.  Human T-cell lymphotropic virus types I and II infections in patients with leukaemia/lymphoma and in subjects with sexually transmitted diseases in Nigeria.

Authors:  O D Olaleye; C C Ekweozor; Z L Li; I E Opala; Z Sheng; T N Onyemenem; S Rasheed
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

6.  Global Prevalence and Risk Factors of Gastro-oesophageal Reflux Disease (GORD): Systematic Review with Meta-analysis.

Authors:  Jorabar Singh Nirwan; Syed Shahzad Hasan; Zaheer-Ud-Din Babar; Barbara R Conway; Muhammad Usman Ghori
Journal:  Sci Rep       Date:  2020-04-02       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.